Skip to main content
. 2015 Apr 20;112(18):5679–5684. doi: 10.1073/pnas.1418962112

Fig. 4.

Fig. 4.

Liposomal display of Apo2L/TRAIL improves its pharmacodynamic profile and enhances antitumor efficacy. (A and B) Nude mice bearing HT-29 xenografts (n = 10 per group) were treated with a single 50 mg/kg dose of Apo2L.0 or Apo2L.L via i.p. for 24 or 48 h then killed. All tumors were collected, homogenized, and assessed for Apo2L/TRAIL using ELISA (A) and caspase-8 activity (B). Error bars denote SEM. (C) Mice (n = 9 per group) bearing HT-29 tumor xenografts were treated with either Apo2L.0 or Apo2L.L via i.p. injection every 2 d. Tumor volumes were measured twice per week and then fit to a nonlinear mixed-effect model of tumor growth (SI Materials and Methods). Overlaid fitted curves are shown on the left and individual tumor volumes and their respective fitted curves are shown on the right. Dashed lines denote mice killed before the end of study.